Join Biotech Showcase in January for Additional Deep Dives on Emerging Healthcare Trends, and Investor and Partnering Meetings

Demy-Colton’s BioFuture™ 2025 conference wrapped up in New York and virtually this week, sounding a positive tone for the biotech industry and the technologies and trends transforming the future of healthcare. The event brought together leaders from biotech, pharmaceutical, digital health, and investment communities for a forward-looking dialogue on innovation, access, and impact.

This year’s event featured 105 speakers, including 39 presenting company speakers, 135 investors, and 49 media on topics including the convergence of artificial intelligence, data science, and biology; advances in diagnostics and bioelectronics; new approaches to therapeutic discovery; and the evolving investment and policy landscape. Speakers included:

• Nouhad Husseini, SVP, Head of Business Development & Corporate Strategy, Regeneron Pharmaceuticals
• Jo Natauri, Founder & Managing Partner, Invidia Capital Management
• Dennis Purcell, Founder & Senior Advisor, Aisling Capital
• Umer Raffat, Senior Managing Director, Evercore ISI
• MaryAnne Rizk, Ph.D., Managing Director, Head of Healthcare & Lifescience Clinical Strategy, Amazon Web Services
• Hans Keirstead, Ph.D., CEO, Immunis, Inc.
• Jennifer Hawks Bland, CEO, NewYorkBIO
• Max Bayer, Pharma Reporter, Endpoints News
• Jennifer Schranz, M.D., SVP & Head of R&D Rare Diseases, Ipsen
• Arda Ural, Ph.D., America’s Industry Markets Leader, Ernst & Young LLP
• Greg Simon, Former Director, White House Cancer Moonshot
• Rachel Sher, Partner, Manatt Health

“We were very encouraged by the positive tone overall shared by leaders at this year’s conference, and very excited about the many companies that participated in our Spotlight Panels, a new format designed to replace standalone company presentations with a more analytic look at the breakthrough therapeutic innovations and cutting-edge technologies shaping key therapeutic areas,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “Innovation thrives when leaders across science, technology, investment, and policy come together. This year’s discussions reflected how the biopharma community is adapting to a changing landscape, balancing optimism with urgency as we harness AI, bioengineering, and global collaboration to ensure innovation reaches patients worldwide.”

Optimism for the future of the industry was a recurring theme throughout BioFuture. In a “Big Think” Plenary session titled, “The Great Biopharma Reset: Will Today’s Challenging Environment Result in a More Resilient Sector?”, one panelist captured this sentiment, noting, “The fundamentals of our industry—innovation in particular, drug launches, medical progress—is as strong as ever and we’re starting to see people care more than they ever cared in a long time.”

In addition to the Therapeutic Spotlight Sessions, BioFuture hosted seed-stage companies as part of a Pitch Doctor Session. Additionally, the conference facilitated hundreds of scheduled partnering meetings, as well as investor and media interviews.

BioFuture’s partnering system remains open through July 31, 2026, allowing registered participants to continue to connect and access company presentations and recorded sessions by logging in with their registration details.

BioFuture’s conversations will continue at Biotech Showcase 2026, the premier investor conference for private and emerging biotechnology companies, taking place January 12-14 in San Francisco. The event brings together thousands of investors, innovators, and media representatives for a week of partnering, presentations, and panels focused on advancing the global biotech ecosystem.

For more information, please visit www.biofuture.com or follow @DemyColton and #BioFuture2025 on LinkedIn and X. For information about Biotech Showcase or to apply to present or sponsor, please visit www.biotechshowcase.com.

About BioFuture™

Sponsored by Aisling Capital, Emerald Bioventures, KKH Advisors, Pappas Capital, Regeneron, Acadia Pharmaceuticals, ENTENTE Network of Companies, EntityRisk, Hogan Lovells, Parexel Biotech, Russo Partners, EisnerAmper, Big4Bio, EY, and NYCEDC, BioFuture is the premier conference where therapeutic pioneers, innovators, investors, and policymakers gather to assess and shape the future of healthcare, digital health, and life sciences innovation.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders. For more information, visit www.demy-colton.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106499754/en/

Innovation thrives when leaders across science, technology, investment, and policy come together.